Mendelspod Podcast

32:38

Two Industry Leaders on Dealing with the Growing...

Mendelspod Podcast ·

2024/05/14

The Clinical Knowledge Base (CKB) powered by The Jackson Laboratory (JAX) is a dynamic digital resource for interpreting complex cancer genomic profiles in the context of gene variant knowledge and protein impact, therapies, and clinical trials. Illumina has teamed up with JAX in the newly released Connected Insights software, which integrates CKB as a knowledge source.We’re joined by Cara Statz from JAX and Erica Schnettler from Illumina to discuss how their combined technologies are helping

en

19:25

Single Cell Spatial Proteomics with Filip Karlsson,...

Mendelspod Podcast ·

2024/05/09

A paper out this week in Nature Methods demonstrates a new technology which shows novel patterns of protein spatial polarization and co-localization in immune cells. The technology launched by Swedish startup Pixelgen has been dubbed “molecular pixelation” because it uses DNA pixels to tag and reveal relative locations. Unlike most other spatial technologies, molecular pixelation does not involve microscopy.Lead author of the paper, Filip Karlsson, joins us today to explain the technology and how it

en

33:59

The Precision Medicine Optimist: Damon Hostin, Illumina

Mendelspod Podcast ·

2024/05/07

Damon Hostin has had an active and exciting journey in genomic medicine. He’s now at Illumina, where his title is illuminative: Lead, Health System Market Access.A regular on the precision medicine stage, Damon has some insights into what he calls the “blindingly fast progression” of genomic medicine that should convince the most jaded of its critics. Compared to other areas of medicine, we are witnessing a rapid uptake of new science. Damon’s biography includes work at Celera in the age of the

en

5:24

An Ethics First Approach to Genetic Research and Drug...

Mendelspod Podcast ·

2024/05/02

This is a free preview of a paid episode. To hear more, visit www.mendelspod.comSarah LeBaron von Baeyer studied anthropology at Yale. Today she serves as the Director of Ethics Engagement at the new drug development company, Variant Bio, not a job she ever imagined at university.

en

28:46

How Do You Train Genomics AI? On Natural Selection...

Mendelspod Podcast ·

2024/04/30

In today’s show, we talk with Kyle Fahr, the VP and Distinguished Scientist leading Illumina’s Artificial Intelligence Lab."We lack a way of training genomics AI as readily as you would for natural language processing, says Fahr. "There are vast amounts of data, but there are no labels, no supervision. One of the most powerful tools that we’ve found is using clues from natural selection.Fahr says the company began the AI lab seven years ago when deep learning took off. Two of the team’s AI

en

5:41

The Pre-Symptomatic Space with Patrick Short, Sano...

Mendelspod Podcast ·

2024/04/25

This is a free preview of a paid episode. To hear more, visit www.mendelspod.comToday, we continue our look into the gap in the adoption of precision medicine. Why are those who need it not getting genetic testing? Patrick Short is the Host of The Genetics Podcast and CEO and Co-founder of Sano Genetics.

en

8:02

Systemwide Implementation of Precision Medicine at...

Mendelspod Podcast ·

2024/04/18

This is a free preview of a paid episode. To hear more, visit www.mendelspod.comThrough its Center for Personalized Medicine, the University of Colorado Health offers its 2.2 million patients some of the country's most advanced precision medicine initiatives.

en

5:03

Is this New Tech a Game Changer for Spatial Biology?

Mendelspod Podcast ·

2024/04/11

This is a free preview of a paid episode. To hear more, visit www.mendelspod.comA new spatial biology company is promising to shake up the field. Last month, Curio Bioscience launched a new technology to early access customers that provides transcriptomic spatial data without the need to b…

en

25:15

Synthetic Biology in 2024 with John Cumbers

Mendelspod Podcast ·

2024/03/26

John Cumbers is back on the show to preview the annual SynBioBeta, the leading global conference for the synthetic biology crowd. This year’s show includes 18 tracks on AI, space, longevity, and DNA synthesis. Speakers will include Stephen Wolfram and Stephen Quake, who will discuss large language models and biology.While 2024 saw a total investment of over $6 billion (not as high as the pandemic year of 2021), John says the new technologies and startups keep coming."We’re seeing just a ton of new

en

30:51

Illumina Scales Variant Calling and Genome...

Mendelspod Podcast ·

2024/03/21

Most of the news coming from Illumina has had to do with their leadership in the sequencing instrument space. What is lesser known is that they offer an end-to-end solution for the clinical lab, including variant calling and genome interpretation.In this podcast, we’re joined by Sam Strom, Principal Scientist at Illumina and a certified Clinical Lab Director. Sam comes to Illumina from the clinical testing side; for example, he’s co-chair for the expert curation panel for Parkinson’s Disease and

en

5:09

The Renaissance in DNA Synthesis Continues: Cosimo...

Mendelspod Podcast ·

2024/03/19

This is a free preview of a paid episode. To hear more, visit www.mendelspod.comToday, we feature a new DNA synthesis company out of Sweden that is making a name with long, single-stranded DNA at scale. How long? Over 10,000 bases. Why single-stranded vs. genes? And what is meant by scale?According to Cosimo Ducani, CEO and co-founder of Moligo Technologies, the business of making DNA is just getting started. So much for thinking it was a mature business in the early 2000s when Integrated DNA

en

22:24

Jennifer Wipf of Ginkgo Bioworks on RNA Therapeutics...

Mendelspod Podcast ·

2024/03/12

The rise of RNA therapeutics and cell therapies promises to take us where we’ve never been in medicine. The growing understanding of RNA, mRNA, and circular RNA and their crucial roles in disease has led to their application in targeting previously “undruggable” targets. Meanwhile, new cell therapies are promising cures to diseases that have plagued us without mercy. Scientists now ask what can’t we do. Still, biology remains dauntingly complex.At the base of these fields is a revolution in

en

5:38

Precision Medicine for Dogs: Christina Lopes, OneHealth

Mendelspod Podcast ·

2024/02/22

This is a free preview of a paid episode. To hear more, visit www.mendelspod.comChapters:0:00 Number one unmet medical need for dogs6:25 Using “extra label” for cross species12:57 Ideal for understanding human cancers21:25 Playing catch-up with human medicine28:04 1,000 pet clinic customersPrecision medicine for dogs?— as in tumor profiling for the right therapies to treat man’s best friends at the right time? Yes, that’s right. …

en

40:29

Taking Gene Therapy to the Next Level: Rahul Kakkar...

Mendelspod Podcast ·

2024/02/15

There’s a new genome editing company that everyone is talking about this year. Tome Biosciences came out of stealth in December, claiming the ability to insert DNA sequences of any size at any location across in vivo and ex vivo modalities. Their website says they’re “taking us into the final chapter of medicine.”Tome’s CEO, Rahul Kakkar, joins us today on the program. He’s a physician-scientist (cardiology) who has previously led a couple of biotech companies, Pandion Therapeutics and Corvidia

en

5:41

Christian Henry of PacBio on Long Reads at Scale,...

Mendelspod Podcast ·

2024/02/13

This is a free preview of a paid episode. To hear more, visit www.mendelspod.com0:00 Long reads at scale has made what difference?6:15 The long or short of it: How does one decide?12:31 Long reads in the clinic20:37 Apton tech to compete with Illumina’s NovaSeq X26:30 Plans for next instruments35:00 Surveying the competitionIn our first post-AGBT show of the year, we’re talking with the CEO of Pacific Biosciences, Ch…

en

40:23

Robert Michel, Editor at The Dark Report, on Gap in...

Mendelspod Podcast ·

2024/02/06

Why aren’t more folks receiving genetic testing?In a study published in JAMA last year, Stanford cancer researcher Alison Kurian found a surprising gap between those who need genetic testing and those who receive it. Among more than a million patients with cancer, only 6.8% underwent germline testing.Today, we begin a new series exploring this gap in testing with Robert Michel. He's the Editor-in-Chief at The Dark Report, reporting on the laboratory industry since 1996. Robert says the problem

en

37:31

Turning to Next Gen Proteomics for Novel Biomarkers:...

Mendelspod Podcast ·

2024/01/30

Batten disease is a group of neurodegenerative lysosomal storage disorders that result from pathogenic variants in one of 13 CLN genes. Collectively, Batten disease affects approximately 1 in 100,000 individuals worldwide, making it the most common pediatric neurodegenerative disorder. The most common form of Batten Disease, CLN3 disease, is a rare and fatal autosomal recessive disorder caused by mutations in CLN3. Individuals with CLN3 disease typically experience vision loss in early childhood,

en

36:24

What Have We Learned from the Brain Map Project So...

Mendelspod Podcast ·

2024/01/23

After ten years, the human brain mapping project has achieved some major milestones, says Tom Nowakowski, a researcher at UCSF, on today’s program. He says that mapping the brain is a “moon shot” easily on par with the Human Genome Project.So much of biology is basic quantification. Brain scientists are beginning to quantify how many kinds of brain cells there are. They are learning more about the function of various cells such as glial cells.. And they are developing a common language with each

en

23:49

Quality Healthcare Should Not Depend on Which Book...

Mendelspod Podcast ·

2024/01/16

Karen Tumulty, a political writer for the Washington Post, was diagnosed with multiple myeloma. She was told she had five years to live. Then she went to book club with friends. On the way home she came out about her diagnosis—and that changed her life. Someone in the car happened to be the President of the Personalized Medicine Coalition, Ed Abrahams. He made a referral and that led to better treatment and better survival. Karen’s story, along with that of her brother, is a must-listen for

en

4:54

Real Probiotics: Colleen Cutcliffe, CEO, Pendulum...

Mendelspod Podcast ·

2024/01/09

This is a free preview of a paid episode. To hear more, visit www.mendelspod.comFun fact: we are composed of 90% bacterial cells and 10% human cells. Surely, the company that begins to turn that knowledge into health products will be the next billion-dollar startup. Pendulum Therapeutics is doing just that. Started in 2012, the company now boasts a full product line of probiotics that are not your typical probiotics. In 2020, the company released a scientific study showing that their glucose

en

All Episodes

Similar Podcasts

Mendelspod Podcast

Theral Timpson

天方烨谈

基因频道

Homesteading and Permaculture by Paul Wheaton

paul wheaton

النشرة العلمية

مونت كارلو الدولية / MCD

Cellal Ko Ngalu

RFI Fulfulde